This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Albany Molecular Research Inc (AMRI)

NASDAQ: Health Care

Company Income Statement
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Sales 276.57M 246.57M 226.69M 207.65M
Cost of Sales 183.54M 155.52M 150.73M 150.31M
Gross Operating Profit 93.03M 91.05M 75.95M 57.33M
Selling, General, and Administrative Expenses 50.52M 45.02M 44.05M 44.76M
Research & Development 1.00M 414.00K 906.00K 7.94M
Operating Income before D & A (EBITDA) 41.51M 45.62M 31.00M 4.64M
Depreciation & Amortization 25.66M 16.40M 17.33M 18.16M
Interest Income 3.00K 11.00K 9.00K 131.00K
Other Income - Net -9.91M 772.00K -130.00K 77.00K
Special Income / Charges -7.83M -1.86M -8.33M -21.34M
Total Income Before Interest Expenses (EBIT) -5.47M 20.96M 582.00K -35.92M
Interest Expense 0.00 1.25M 463.00K 714.00K
Pre-Tax Income -5.47M 19.70M 119.00K -36.64M
Income Taxes -2.19M 7.02M 3.90M -4.34M
Minority Interest 0.00 0.00 0.00 0.00
Net Income From Continuing Operations -3.28M 12.68M -3.78M -32.30M
Net Income From Discontinued Operations 0.00 0.00 0.00 0.00
Net Income From Total Operations -3.28M 12.68M -3.78M -32.30M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income -3.28M 12.68M -3.78M -32.30M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
8.14M 21.72M 9.19M -9.68M
Preferred Dividends
Net Income Available To Common -3.28M 12.68M -3.78M -32.30M
Basic EPS from Continuing Ops. -0.10 0.41 -0.12 -1.08
Basic EPS from Discontinued Ops. 0.00 0.00 0.00 0.00
Basic EPS from Total Operations -0.10 0.41 -0.12 -1.08
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total -0.10 0.41 -0.12 -1.08
Basic Normalized Net Income/Share 0.26 0.70 0.30 -0.32
EPS fr Continuing Ops. -0.10 0.41 -0.12 -1.08
EPS fr Discontinued Ops 0.00 0.00 0.00 0.00
EPS fr Total Ops. -0.10 0.41 -0.12 -1.08
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 -0.01 0.00 0.00
EPS, Total -0.10 0.40 -0.12 -1.08
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0.26 0.70 0.30 -0.32
Dividends Paid per Share 0.00 0.00 0.00 0.00
AMRI News

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

AMRI Albany Molecular Research Inc

Chart of AMRI

Analysts Ratings for AMRI

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 2 2 2 2
Moderate Buy 1 1 1 1
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET AMRI ANALYST REPORT

AMRI Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs